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Abstract
Objective
To compare the immunogenicity of three yellow fever vaccines from WHO-17D and
Brazilian 17DD substrains (different seed-lots).
Methods
An equivalence trial was carried out involving 1,087 adults in Rio de Janeiro. Vaccines
produced by Bio-Manguinhos, Fiocruz (Rio de Janeiro, Brazil) were administered
following standardized procedures adapted to allow blocked randomized allocation of
participants to coded vaccine types (double-blind). Neutralizing yellow fever antibody
titters were compared in pre- and post-immunization serum samples. Equivalence
was defined as a difference of no more than five percentage points in seroconversion
rates, and ratio between Geometric Mean Titters (GMT) higher than 0.67.
Results
Seroconversion rates were 98% or higher among subjects previously seronegative,
and 90% or more of the total cohort of vaccinees, including those previously
seropositive. Differences in seroconversion ranged from -0.05% to -3.02%. The
intensity of the immune response was also very similar across vaccines: 14.5 to 18.6
IU/mL. GMT ratios ranged from 0.78 to 0.93. Taking the placebo group into account,
the vaccines explained 93% of seroconversion. Viremia was detected in 2.7% of
vaccinated subjects from Day 3 to Day 7.
Conclusions
The equivalent immunogenicity of yellow fever vaccines from the 17D and 17DD
substrains was demonstrated for the first time in placebo-controlled double-blind
randomized trial. The study completed the clinical validation process of a new vaccine
seed-lot, provided evidence for use of alternative attenuated virus substrains in vaccine
production for a major manufacturer, and for the utilization of the 17DD vaccine in
other countries.
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Resumo
Objetivo
Comparar a imunogenicidade de três vacinas contra febre amarela ) das subcepas
WHO-17D e 17DD brasileira (diferentes lotes-semente).
Métodos
Trata-se de ensaio de equivalência envolvendo 1.087 adultos no Rio de Janeiro, RJ. As
vacinas foram produzidas em Bio-Manguinhos, Fiocruz (Rio de Janeiro, Brasil) e
foram administradas seguindo procedimentos adaptados para randomização em
blocos, com tipos de vacinas codificados (“duplo-cego”). Anticorpos neutralizantes
contra febre amarela foram dosados antes e depois da vacinação. Definiu-se
equivalência como diferença nas taxas de soroconversão não superior a cinco pontos
percentuais, e razão de títulos médios geométricos superior (TMG) a 0,67.
Resultados
As taxas de soroconversão foram iguais ou maiores do que 98% nos participantes
previamente soronegativos. Na coorte completa (incluindo os previamente
soropositivos) a soroconversão foi igual ou superior a 90%. As diferenças na
soroconversão variaram de -0,05% a -3,02% entre os grupos de comparação. A
intensidade da resposta imune também foi semelhante nos grupos: 14,5 UI/mL a
18,6 UI/mL. As razões de TMG variaram de 0,78 a 0,93. Considerando o grupo
placebo, as vacinas explicaram 93% da soroconversão. Viremia foi detectada entre
os dias três e sete em 2,7% dos participantes vacinados.
Conclusões
A equivalência na imunogenicidade das vacinas contra a febre amarela das subcepas
17D e 17DD foi demonstrada pela primeira vez em ensaio clínico randomizado,
duplo-cego, controlado com placebo. O estudo completou o processo de validação
clínica do novo lote-semente de vacina, além de ampliar as bases para utilização da
vacina brasileira em outros países e de trazer alternativas de subcepas para o produtor
da vacina no Brasil.
INTRODUCTION
Yellow fever (YF) is an acute viral disease of public
health importance in Africa and South America, and
of interest for travel clinics in other areas of the world.
There is concern about the potential for urban out-
breaks of YF in Latin America with the increase in the
distribution of the Aedes aegypti, increased intrusion
of people into forested areas, and low vaccine cover-
age.23,25 In Brazil the number of reported YF cases has
been increasing in the last ten years peaking in 2000
(85 cases), and approaching more densely populated
areas in the Southeast.
YF vaccines have been available since the1930’s
and constitute the most important method to control
the disease. YF vaccines recommended by the World
Health Organization (WHO) are from 17D and 17DD
substrains, which have minor differences in nucle-
otide sequences.6 Control of viral substrains and se-
rial passage levels through the seed lot system were
implemented in the 1940’s to avert unwanted altera-
tions in biological properties of the vaccine.4 YF vac-
cines are now considered safe and highly immuno-
genic.16,25 Protective antibodies induced by the vac-
cine are experimentally correlated to infection resist-
ance, and have long duration, possibly life long.8,18
Bio-Manguinhos-Fundação Oswaldo Cruz, which
is a WHO-prequalified manufacturer linked to the
Brazilian Ministry of Health supplies YF vaccine for
Brazil and other countries in South America and Af-
rica. From 2000 to 2004, 26,368,050 doses of YF vac-
cine have been exported to 50 different countries in
South and Central America, Africa and Asia. In Brazil
77,374,755 doses were administered from 1994 to
2002. As the working seed lot was used up a new seed
lot was prepared and tested, confirming the genetic
stability of the virus, its safety in the monkey neuro-
virulence test (unpublished data), and freedom from
avian leucosis infectious virus.11 As part of the proc-
ess of clinical validation of the new seed lot, it was
compared the immunogenicity and reactogenicity of
a vaccine produced from this new seed lot to that of
the already licensed vaccine, to the vaccine produced
from WHO 17D-203/77 substrain seed lot, and to pla-
cebo. This paper reports the results of immunogenic-
ity component of the trial. Data on reactogenicity
will be the subject of another publication.
METHODS
A randomized field trial was carried out to test the
equivalence of three vaccines in their seroconversion
rates for YF and geometric mean antibody titters
Descritores
Vacina contra febre amarela. Ensaios
controlados aleatórios.
  	
 
 ! 
"#" 
Immunogenicity of yellow fever vaccines
Camacho LAB et al
(GMT), and to measure the rates of adverse events,
abnormalities in liver enzymes and levels of viremia
up to 30 days after immunization. The intent was to
demonstrate that the vaccine from the new seed-lot
of the 17DD substrain was at least as immunogenic as
the vaccine from the working seed-lot of the 17DD
substrain and a vaccine from the WHO-17D seed-lot.
Vaccine and placebo vials were labeled with codes
concealed from the participants and the field work
team. Participants in the placebo group were vacci-
nated against YF after the scheduled opening of the
codes. The research protocol was approved by Re-
search Ethics Committees from Fundação Oswaldo
Cruz and from the Brazilian Army. Placebo was scien-
tifically justified for a precise assessment of the reac-
togenicity and immunogenicity of the vaccines. It
was ethically acceptable since the study area has been
free of YF, and immunization was not routinely con-
ducted there. Two independent reviewers examined
the study protocol and the preliminary results and
reported to the steering committee.
Eligibility assessment, recruitment of participants,
administration of vaccines and blood collection were
carried out in 21 units of the Army located in Rio de
Janeiro, Brazil. Eligibility criteria were age 18 years
or more, no previous vaccination against YF, no plans
to travel to YF endemic areas during the study period,
availability for study follow-up, and signed an in-
formed consent. Vaccination history had to be relied
on information from participants. The following con-
ditions constituted exclusion criteria: (1) pregnancy;
(2) immunosuppression due to diseases or immuno-
suppressive therapy; (3) history of hypersensitivity
to chicken eggs; (4) administration of any vaccine
30 days before this vaccination; and (5) other severe
disease or fever of 38ºC or higher.
Trained nurses adjusted routine immunization pro-
cedures to meet the requirements for blinding and ran-
domization. Participants received a single 0.5 ml sub-
cutaneous injection in the deltoid region of one of
four products: (i ) 17DD vaccine (lot 993PFBEXP03;
passage 287) produced from new seed-lot; (ii) 17DD
vaccine (lot 999FB060Z; passage 286; licensed and
available at the time of the trial); (iii) 17D vaccine (lot
# 007FBEX01; passage 239) produced from a second-
ary seed-lot WHO 213/77/Br 1B/86; and (iv) placebo
made of chicken embryo juice material without YF
virus. All vaccines were produced by the Institute of
Immunobiological Technology in Fundação Oswaldo
Cruz, Rio de Janeiro. Vaccines were lyophilized, ther-
mostable, and contained ≥1,000 MLD
50
 in each 0.5-
ml dose. Vaccines and placebo contained sodium gluta-
mate, sucrose and <5.0 mg of ovalbumin per dose. Dis-
tribution, handling and administration of the vaccine
followed recommendations from the manufacturer and
the Brazilian Program of Immunization.14 Briefly,
freeze-dried vaccines (or placebo) in 50-doses vials
were diluted in sterile and apyrogenic saline solution,
kept between 2ºC and 8ºC, protected from light, and
discarded after four hours.
Vaccine and placebo vials looked identical and
were labeled with codes, which were concealed from
study participants, field work team, laboratory staff,
and data analysts. The computer-generated randomi-
zation scheme (block length =12; uniform allocation
ratio) was also concealed in opaque envelopes, which
were opened in predetermined sequence at the time
of vaccine administration.
Seroconversion was defined as doubling of pre-vac-
cination antibody titters and as seropositivity among
individuals with seronegative results in the pre-vac-
cination test. The antibody titter was measured with
the Plaque Reduction Neutralization Test (PRNT).5,17
Serologic analyses were conducted at the Laboratory
of Viral Technology at Fundação Oswaldo Cruz.
Venous blood samples were drawn just before, be-
tween Days 4 and 20, and 30 days or more after vac-
cination. Serum aliquots were coded to conceal the
identity of the participant and the timing of collec-
tion (pre/post-vaccination). PRNT was conducted in
serial two-fold dilutions starting at 1:5, in 50 µl of
inactivated serum in 96 well tissue culture plates.
Thirty plaque forming units (pfu) of 17D strain of YF
virus in 50 µl were dispensed into all wells. Dilutions
of virus and serum were performed in 199 medium
containing 2.5% 1M HEPES. A positive monkey se-
rum sample with YF antibody content calibrated by a
WHO International Reference Preparation was in-
cluded in each set of test. After incubation at room
temperature for 1 hour, 50 µl of a suspension of Vero
cells in 199 medium in a density of 1.6x105 cells/
well was added to all wells and the plates incubated
at 37ºC in 5% CO
2
 atmosphere for 3 hours. The me-
dium was discarded and replaced with 199 medium
containing 3.5% carboxymethyl cellulose in volumes
of 100 µl. After incubation at 37ºC in 5% CO
2
 atmos-
phere for seven days, the monolayers were fixed with
formalin, stained with crystal violet and plaques
counted at a magnification of x 12.5 on a vertically
mounted 35 mm projector with wide angle lens. The
log
10
 dilution of the test and standard serum, which
reduced the plaque numbers by 50% relative to the
virus control was determined by linear regression.
The mean antibody titter at the 50% endpoint of the
standard serum was then calculated and added to the
log
10
 endpoint for each sample to give log
10
 mIU/ml.
Seropositivity was defined as YF virus neutralizing
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antibody titter equal to or higher than 630 mIU/ml
(2.8 log
10
). The inter-rater agreement of antibody tit-
ters was assessed through independent tests performed
in duplicate serum aliquots in a 20% sub-sample of
participants.
Signs and symptoms experienced after immuniza-
tion were ascertained in an interview and in diary
forms filled in by participants. Serum levels of liver
enzymes aspartate aminotransferase (AST), alanine
aminotransferase (ALT), gamma-glutamyl transpepti-
dase (GGT) and alkaline phosphatase (AP) were meas-
ured in all serum samples. Levels of viraemia were
measured in the second (intermediate) blood sample
collected between Days 4 and 20 using methods de-
scribed elsewhere.9
For a one-sided, non-inferiority equivalence trial it
was appropriate to calculate the differences in sero-
conversion rates among the vaccine groups, and the
ratios of GMT, with appropriate 90% confidence in-
terval (90% CI) set by the conventional value of 0.05
for α-error.3 The vaccines were considered similar if
the lower limit of the difference did not exceed -5%
and the lower limit of the ratio of GMT were not less
than 0.67.
From the comparisons between each vaccine and
the placebo it was derived proportions of seroconver-
sion attributable to the vaccine, with 95% CI.2 Anti-
body titters from vaccines and placebo were com-
pared in reverse cumulative distribution plots.19
Agreement between titters in the subset of sera with
two aliquots was measured with the intraclass corre-
lation coefficient.1 Analyses were conducted both for
the complete study cohort (intention-to-treat analy-
sis) and for those who met all protocol requirements.
Sample size was based on a null hypothesis of non-
equivalence and alternative hypothesis of equiva-
lence. For beta =0.20, alpha =0.05, a difference no
higher than 5 percentage points, 95% seroconversion
rate and 10% attrition rate, the required number in
each group was 240.1 Epi Info 6.04c and SPSS 10,
1999 were used for data entry and statistical analysis.
RESULTS
From January to May 2001, 1,087 volunteers re-
ceived vaccine or placebo, donated pre-vaccination
blood sample and were interviewed. Six (0.6%) of
them did not return for post-vaccination blood col-
lection for reasons unrelated to adverse events. Sera
of three individuals were not available for analysis.
Three received other vaccines during the follow-up
and one was 15 years old. A large proportion of par-
ticipants were found to be seropositive in pre-vacci-
nation tests (Table 1). They had a balanced distribu-
tion across comparison groups, included the same
proportion of males, but were older than those with
seronegative pre-vaccination tests (median age of 33
and 24 years, respectively).
The age of participants ranged from 14.8 to 67.7
years, with comparable means and standard devia-
tions across groups (Table 1). Young males were highly
predominant.
In general, the vaccine was well-tolerated and
there were no reports of severe adverse events. A
detailed account of the vaccine reactogenicity is
reported elsewhere.
Table 1 - Number and selected characteristics of participants by intervention group (vaccines and placebo). Rio de Janeiro, 2001.
Intervention
17DD-013Z* 17DD-102/84** 17D-213/77*** Placebo Total
Number recruited 270 273 272 272 1,087
Number with complete follow-up 270 270 270 271 1,081
Age (years)
Mean 28.1 29.3 28.4 29.3 28.8
Standard deviation 8.6 10.2 8.8 9.4 9.3
% of males 91.5 91.6 94.1 94.5 92.9
Seropositivity to pre-vaccination test  (N, %)61 (22.6) 77 (28.2) 59 (21.7) 71 (26.1) 268 (24.7)
Vaccines produced from  *New seed lot;  **Current seed lot; ***WHO seed lot
Table 2 - Proportion of seroconversion and post-immunisation seropositivity to yellow fever, and geometric mean titter (GMT)
by intervention group, and analytical approach. Rio de Janeiro, 2001.
Intervention
Endpoint Analytical approach 17DD-013Z* 17DD-102/84** 17D-213/77*** Placebo
% of seroconversion****
intention-to-treat***** 90.0 90.8 93.0 9.2
per protocol****** 98.0 99.5 99.5 6.4
GMT in the post-vaccination test
Intention-to-treat***** 14,059 15,107 17,920 94
per protocol****** 14,536 15,691 18,649 32
Vaccines produced from: *New seed lot; **Current seed lot; ***WHO seed lot; ****Two-fold increase in pre-vaccination
antibody levels; *****Complete cohort; ******Excluding individuals who were seropositive in the pre-vaccination test.
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The proportion seropositive after vaccination was
above 97% in the complete cohort as well as in the
subset seronegative before vaccination. The immuno-
logical response to all three types of vaccine was simi-
lar in the whole range of antibody titters (Figure 1).
The mean and the median antibody titters were similar
for the vaccines (Table 2). More than 90% of those
who received one of the vaccines, including the sero-
positive in the pre-vaccination test, showed at least a
two-fold increase in their antibody levels (Table 2).
Excluding participants with seropositive pre-vac-
cination tests, seroconversion was above 98% among
vaccinated groups (Table 2). GMT from the
whole cohort were very close to GMT ob-
tained in per protocol analysis.
The intraclass correlation coefficient (ICC)
for antibody titters in two aliquots of the
same sera was 0.79 (95% CI: 0.74-0.83). The
distribution of the differences between tit-
ters was symmetrical, with mean 0.12 and
median 0 log
10
 mIU/ml. With seroconversion
defined as fourfold increase in pre-vaccina-
tion titters, the rates would have been 96.6%,
98.4%, 98.5% and 2.1% for vaccines pro-
duced from 17DD-013Z, 17DD-102/84, 17D-
213/77 seed lots and placebo, respectively.
The unexpected substantial proportion of
individuals seropositive to YF before inter-
vention engendered an analysis of this subset
that had not been considered in the protocol.
They showed seroconversion rates of 67%,
76%, 77% and 16% in the groups that received
the vaccines produced from 17DD-013Z,
17DD-102/84, 17D-213/77 seed-lots and the
placebo, respectively. The variation in the pla-
cebo group suggested that part of the sero-
conversion of vaccines was not explained by
the vaccine. Contrasting the pool of vaccines
with placebo controls, the proportion of sero-
conversion attributable to immunization was
79% among those with pre-vaccination se-
ropositivity. The post-vaccination GMT was
somewhat higher among vaccinated subjects
who were seronegative (16.2 IU/ml; 95% CI:
14.7-17.8 IU/ml) before vaccination, com-
pared to those who were seropositive (14.0
IU/ml; 95% CI: 12.0-16.3 IU/ml).
Analysis of the complete cohort indicated
that 90% of seroconversion among vacci-
nated subjects were attributable to the vac-
cines. Excluding the seropositive before vac-
cination, study vaccines explained more than
93% of seroconversion of vaccinated subjects.
The differences between the proportions of post-
vaccination seropositivity varied from 0.35% to -
1.95% with lower confidence limits above -5% (data
not shown). Differences in seroconversion ranged
from -0.05% to -3.02% (Figure 2). The lower limit of
the 90% confidence interval of the difference between
17DD vaccines and the 17D vaccine was beyond the
limit of equivalence.
The ratios of post-vaccination GMT ranged from
0.78 and 0.93, and the 90% CI from vaccines pro-
Figure 1 – Reverse cumulative distribution of antibody titers after yellow
fever vaccines or placebo, excluding subjects seropositive before
vaccination. Rio de Janeiro, 2001.
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Figure 2 – Differences in proportions of seroconversion (percent and
90% confidence limits) between three yellow fever vaccines, for the
complete cohort and for the subset seronegative in the pre-vaccination
test. Rio de Janeiro, 2001.
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duced from 17DD-013Z and 17D-213/77 seed lots
included the 0.67 limit defined as equivalence (data
not shown).
Viremia was detected in only 2.7% of vaccinated
subjects (2.2% of those who received 17DD and 3.7%
with 17D), from Day 3 to Day 7 after vaccination.
Seroconversion rates for the three vaccine groups
pooled together differed slightly across age-groups:
30 years or more, 95.4%, 25-29 years, 99.5% and 18-
24 years, 99.7%. The GMT for vaccines did not differ
substantially across those age groups, though (17.6,
18.0 and 17.7 IU/ml, respectively). Female volunteers
(n=54) showed a smaller seroconversion rate com-
pared to men: 95.5% and 99.3%, respectively. Again,
the GMT did not differ substantially: 17.9 UI/ml
(women) and 17.8 UI/ml (men).
DISCUSSION
YF vaccines have been shown to induce long-last-
ing protection. Notwithstanding, the immunogenic-
ity of the YF vaccine has been questioned in recent
publications.10,21,25 It was assessed the performance of
the YF vaccines under Good Clinical Practice guide-
lines, as part of the clinical validation of a new seed-
lot, used to supply vaccines to the National Immuni-
zation Programs in Brazil and other parts of Latin
America and Africa. Brazil is the only producer and
the major consumer of a 17DD substrain YF vaccine,
which had never been compared in controlled stud-
ies with the 17D substrain and with placebo. Those
elements along with the blinding and the equiva-
lence type of design expanded the possibilities of
analyses and increased confidence in the results.
The results indicated that the vaccines prepared with
WHO-17D substrain and the Brazilian 17DD substrain
induced satisfactory immunological response. High
seroconversion rates and GMT in international units
were comparable to those reported in other randomized
trials,12,15 and in observational studies in adults, in
which neutralization tests were used to assess immu-
nological response and the 17D strain vaccine was
used.16,20,22,24 Comparability with previous results is
limited by methodological differences, such as labo-
ratory methods for antibody titration, vaccine dose and
method of administration, and age of study subjects.
That is the case of three studies involving the 17DD
substrain. Lopes et al13 reported 100% seroconversion
with a 600 LD
50
 /dose vaccine; Guerra et al10 observed
76% seropositivity detected through mouse neutrali-
zation tests six months after vaccination with jet injec-
tors; and Stefano et al21 obtained 78% seroconversion
rate among 9-month-old infants.
A substantial proportion of participants in the
present study showed pre-vaccination seropositivity
probably as a result of previous vaccination, which
they ignored or concealed. Previous natural YF in-
fection was less likely as the study site was neither
endemic nor epizootic. As PRNT is considered highly
specific, previous infections by other flaviruses were
not expected to cause false-positive results.17 There
were no striking imbalances in the distribution of
pre-vaccination seropositivity across vaccination and
placebo groups that could affect their comparability.
Most of the subjects with pre-vaccination seroposi-
tivity showed immunological response to
(re)vaccination, but the differences among compari-
son groups did not change substantially when they
were included in the analysis.
Analysis considering only those seronegative to
YF in the pre-vaccination test (per protocol analysis)
showed excellent immunogenicity of the vaccines.
The differences between proportions of seroconver-
sion were never beyond 3%, but for some contrasts,
the 90% CI included values outside the range defin-
ing equivalence. This evidence against equivalence
should take into account the practical implications
of the arbitrary 5% difference in seroconversion rates,
and 1.5 ratio in GMT, which are conservative. The
lowest confidence limit of -7% in the difference be-
tween the new seed-lot and the WHO seed-lot repre-
sented the worst scenario of the complete cohort with
substantial proportion of individuals less likely to
show immunological response to vaccination. For
practical purposes, the data provided evidence that
there was equivalence between the two seed-lots of
the 17DD vaccine in terms of seroconversion and
magnitude of immune response.
The apparent “seroconversion” in the placebo
group may be including genuine fluctuations in the
level of previously existing antibodies and variabil-
ity of laboratory methods. The effect of unreliability
of measurements is attenuation of effect measures and
non-differential misclassification,7 which may lead
to underestimation of the proportion of seroconver-
sion attributable to the vaccine compared to placebo.
In the present study, a more stringent definition of
seroconversion (fourfold increase in pre-vaccination
titters) had little impact on the observed rates and
differences between vaccines.
The attributable proportion of seroconversion
among vaccinated, a measurement analogous to effi-
cacy, estimated the “net effect” (accounting for “se-
roconversion” in placebo controls) of vaccination,
which was greater in the present study than in an-
other study.10 Seropositivity has been generally con-
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sidered to indicate protection against natural infec-
tion, although direct evidence is lacking in human
beings. Serological correlates of protection against
YF are based on data from non-human primates.8 Ef-
ficacy trials have never been performed so that, in
addition to pre-clinical data, evidence of effective-
ness of the YF vaccine relies on indirect evidence
provided by correlation of disease occurrence and
vaccination coverage in several endemic areas over
the years.16
Gender differences in vaccine immunogenicity
found in other studies 15 were not confirmed in the
present study. Differences in proportion of serocon-
version seemed to favor individuals less than 30 years
old, but the magnitude of immune response did not
confirm the advantage. That converges with results
obtained by Monath and colleagues.15 Generaliza-
tion of the results to age groups not included in this
study, particularly children below two years of age,
are not warranted considering the potential interfer-
ence of maternal immunity and concomitant admin-
istration of other vaccines.
The levels and the duration of viremia after YF vac-
cination are in accordance with previous findings in
the literature.16 Their implications for safety will be
analysed in another paper.
In conclusion, the vaccine produced from a new seed-
lot generated from a single passage of the 17DD-102/
84 seed-lot showed high immunogenicity, and could
replace the original seed-lot for the production of the
YF vaccine. The similar performance of the 17D and
17DD vaccines is significant from the perspective of
vaccine supply in YF endemic countries. The 17DD
substrain is produced only in Brazil but is distributed
in other Latin American and African countries where
17D vaccines have been utilized. Moreover, the re-
sults indicated a choice of vaccine virus for the vac-
cine manufacturer in Brazil. The placebo group allowed
a more precise estimation of the effect of vaccination
accounting for concurrent changes unrelated to vacci-
nation, and shortcomings of serologic methods.
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